(39 days)
EZYSure™ OneStep Ovulation Predictor Home Test Kit is Excel Scientific. Inc.'s name for OTC use of solld phase 1. immunoassay in vitro diagnostic test kit for the qualitative determination of Luteinizing Hormone (LH) in urine
The EZY Sure™ OneStep Ovulation Prodictor Homo Test Kit is a sandwich solld phase dye-conjugato non-enzyme immunoassay. As the specimen is added to the reaction device, the gold-sol-antibody conjugate binds to the LH in the specimen forming an antibody-antigen complex birds to the anti-LH antibody in the positive reaction zone and produces a rese pink color band when LH concentration is present in the abserve of LH, there is no rosepink line in the postive reaction cultinues to flow through the absorbent device, pass the positive reaction zurie, producing a rose-pink color band, demonstrating that the reagents and device are functioning correctly.
Here's an analysis of the provided text regarding the EZYSure™ OneStep Ovulation Predictor Home Test Kit, structured according to your request:
Acceptance Criteria and Device Performance Study
1. Table of Acceptance Criteria and Reported Device Performance
| Acceptance Criteria Category | Specific Acceptance Criteria | Reported Device Performance |
|---|---|---|
| LH Surge Detection | Capable of discerning LH concentration between 25-30 mIU/mL | Capable of discerning an LH concentration between 25-30 mIU/mL in the urine. When the LH concentration in the urine is ≥ 30 mIU/mL, it is indicative that LH surge is in progress. |
| Interference | No interference from homologous hormones (1,000 mIU/mL hFSH or 1,000 µIU/mL TSH) | Not interfered by the presence of homologous hormones (such as 1,000 mIU/mL hFSH or 1,000 µIU/mL TSH). |
| No interference from common drugs (acetaminophen, aspirin, atropine, caffeine, gentisic acid, each at 20 mg/dL) | Not interfered by common drugs (such as acetaminophen, aspirin, and, atropine, caffeine or gentisic acid, each at 20 mg/dL). | |
| No interference from other substances (2 g/dL glucose, 1 mg/dL hemoglobin, 20 mg/dL ampicillin, 20 mg/dL tetracycline) | Not interfered by other substances (such as 2 g/dL glucose, 1 mg/dL hemoglobin, 20 mg/dL ampicillin, or 20 mg/dL tetracycline) in the specimen. | |
| User Performance (Lay User) | Consumers (lay users) should be able to obtain results equivalent to those obtained by trained laboratory technicians. | Consumers (103 female volunteers) were able to obtain results that were equivalent to those obtained by trained laboratory technicians who employed another commercially available one-step ovulation test (Conceive® by Quidel) and a quantitative microtiter EIA LH assay (Medix) on the same patient urine specimens. |
| Intra- and Inter-Assay Variation | No detectable intra- and inter-assay variation between reagent lots and between different reagent lots. | No detectable intra- and inter-assay variation between reagent lots and between different reagent lots using spiked urine pool or patient specimens with known LH concentrations have been substantiated. |
| Shelf-Life | Eighteen-month shelf-life. | An eighteen-month shelf-life has been substantiated by the real-time and accelerated stability testing of the sample reagent. |
2. Sample size used for the test set and the data provenance
- Sample Size: 103 female volunteers (for the user performance study).
- Data Provenance: The document does not explicitly state the country of origin. It indicates the study used "patient urine specimens," which suggests a prospective collection for the purpose of the study. It refers to a comparison with a quantitative microtiter EIA LH assay (Medix) on the "same patient urine specimens," implying these were freshly collected or used within an appropriate timeframe for LH testing.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts
- Number of Experts: This test directly compares lay user results to those obtained by "trained laboratory technicians." The document does not specify a number of technicians, nor their specific qualifications (e.g., certification, years of experience), beyond being "trained." The Medix quantitative microtiter EIA LH assay served as the gold standard for LH level determination, which is an objective measurement rather than an expert interpretation of the device itself.
4. Adjudication method for the test set
- The document implies a direct comparison, where the results obtained by the lay users with the EZYSure™ test were compared against the results from the Conceive® test (also read by trained laboratory technicians) and the Medix quantitative EIA LH assay. There’s no explicit mention of an adjudication method (like 2+1 or 3+1 consensus) for discrepancies between readings. The "equivalence" implies statistical comparison rather than a formal adjudication process amongst human readers for the device interpretation.
5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
- No, a multi-reader multi-case (MRMC) comparative effectiveness study was not done. This device is a home test kit for a biochemical marker (LH), not an imaging or diagnostic AI tool. The study involved comparing lay user performance with the device against laboratory technician performance using an existing test and a quantitative assay. It does not involve "AI assistance" or "human readers" in the context of interpretation that would typically necessitate an MRMC study.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
- Yes, in essence, standalone performance was demonstrated through the inherent design of the test. The EZYSure™ OneStep Ovulation Predictor Home Test Kit is designed as a standalone, qualitative diagnostic device. The performance criteria related to LH surge detection, interference, and intra/inter-assay variation represent the "algorithm only" performance (the chemical reaction and visual readout mechanism) independent of user interpretation, though the final interpretation by the user is part of the "user performance" study. The test kit produces a visual colored band; there is no separate "algorithm" in the modern sense of AI.
7. The type of ground truth used
- The ground truth for LH surge detection and LH concentration was established by objective quantitative measurement: a quantitative microtiter EIA LH assay (Medix) on the same urine specimens.
- For user performance, the ground truth for comparison was the results obtained by trained laboratory technicians using both the comparative Conceive® test and the gold-standard Medix quantitative EIA LH assay.
8. The sample size for the training set
- The document does not explicitly mention a training set sample size. This is common for this type of in-vitro diagnostic device, as "training" often refers to the development and optimization of the chemical reagents and manufacturing process rather than a specific data-driven machine learning training phase. The described studies are primarily validation studies.
9. How the ground truth for the training set was established
- Since a formal "training set" in the context of machine learning is not mentioned, the concept of establishing ground truth for it is not applicable here. The development and optimization of the EZYSure™ OneStep Ovulation Predictor Home Test Kit would have involved internal R&D, likely using characterized urine samples (spiked with known LH concentrations, or verified by established lab methods) to refine the sensitivity, specificity, and visual readout characteristics of the immunoassay. However, the document does not detail this developmental phase or any specific "training set" used therein.
§ 862.1485 Luteinizing hormone test system.
(a)
Identification. A luteinizing hormone test system is a device intended to measure luteinizing hormone in serum and urine. Luteinizing hormone measurements are used in the diagnosis and treatment of gonadal dysfunction.(b)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.